Published in J Transl Med on January 25, 2007
The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunol Immunother (2009) 1.06
Intravenous ascorbic acid to prevent and treat cancer-associated sepsis? J Transl Med (2011) 0.81
Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science (2003) 14.04
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 13.10
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science (1999) 11.04
Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature (1986) 9.73
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature (2005) 7.18
Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med (2002) 6.11
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med (1999) 6.09
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol (2005) 5.36
Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science (2005) 4.32
Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol (2002) 4.21
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood (2002) 4.00
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood (2002) 3.60
Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol (2004) 3.27
Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res (2005) 2.91
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med (2000) 2.78
Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J Immunol (2003) 2.34
Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol (2002) 2.32
NKG2D function protects the host from tumor initiation. J Exp Med (2005) 2.19
Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw (2000) 2.11
ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. Carcinogenesis (2003) 1.96
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer (2005) 1.82
Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest (2003) 1.70
Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation (2003) 1.62
HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry. Leukemia (2000) 1.49
Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst (2005) 1.46
Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology (2005) 1.45
Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient. Br J Cancer (1977) 1.43
Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol (2004) 1.39
The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J Immunol (2005) 1.31
Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol (2005) 1.30
Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res (2005) 1.30
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A (2001) 1.30
Expression of C-type lectin receptors by subsets of dendritic cells in human skin. Int Immunol (2004) 1.29
Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother (2005) 1.25
Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc Natl Acad Sci U S A (2005) 1.24
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood (2000) 1.23
Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol (2003) 1.22
Naturally arising CD25+CD4+ regulatory T cells in tumor immunity. Curr Top Microbiol Immunol (2005) 1.22
Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol (2005) 1.16
Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J Clin Invest (2001) 1.14
Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol (2003) 1.11
Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia (2005) 1.10
The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol (2000) 1.10
The role of anergy in peripheral T cell unresponsiveness. Life Sci (1994) 1.09
Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood (1997) 1.09
Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res (2005) 1.09
Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood (1996) 1.08
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood (2003) 1.07
CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood (1995) 1.03
A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer (1996) 1.03
Maintenance of clonal anergy by endogenously produced IL-10. Int Immunol (1994) 1.02
Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy (2003) 1.01
Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res (1993) 0.99
CD4+CD25+ regulatory T lymphocytes in malignant pleural effusion. Am J Respir Crit Care Med (2005) 0.99
The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. Blood (2005) 0.98
Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor. J Clin Invest (1991) 0.98
Immune response modifiers--mode of action. Exp Dermatol (2006) 0.97
RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp Hematol (2005) 0.97
Interleukin-2-activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo. Blood (1992) 0.96
T-cell immunity to the joining region of p210BCR-ABL protein. Proc Natl Acad Sci U S A (1992) 0.95
Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. Br J Dermatol (2006) 0.95
Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha. Clin Cancer Res (2000) 0.91
Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J Infect Dis (1998) 0.91
BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib. Cancer Genet Cytogenet (2005) 0.90
Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochem Biophys Res Commun (2005) 0.89
Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood (1996) 0.89
Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood (1995) 0.88
The influence of CD25+ cells on the generation of immunity to tumour cell lines in mice. Novartis Found Symp (2004) 0.87
Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod. Leuk Lymphoma (2005) 0.87
BCR/ABL promotes dendritic cell-mediated natural killer cell activation. Cancer Res (2005) 0.86
Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream. Dermatol Surg (2005) 0.85
Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study. J Dermatol (2004) 0.85
Imiquimod 5% cream (Aldara). Expert Opin Investig Drugs (1998) 0.85
Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood Cells Mol Dis (2002) 0.85
Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine. Vaccine (2001) 0.84
Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor. Nat Immun Cell Growth Regul (1991) 0.81
The role of immunotherapy in acute myelogenous leukemia. Arch Intern Med (1983) 0.81
Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Australas J Dermatol (2006) 0.80
Current CML therapy: progress and dilemma. Leukemia (2003) 0.80
NK cell sensitivity of the leukemic K 562 cells; effect of sodium butyrate and hemin induction. J Immunol (1982) 0.80
Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha. Leuk Lymphoma (1995) 0.79
Glivec and CML: a lucky date. J Biol Regul Homeost Agents (2005) 0.79
Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma (1998) 0.78
Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients. Clin Cancer Res (2000) 0.78
Treatment of chronic myelogenous leukemia with autologous bone marrow transplantation followed by roquinimex. Bone Marrow Transplant (1999) 0.78
In-vivo generation of leukaemia-derived dendritic cells. Best Pract Res Clin Haematol (2004) 0.77
Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2. Cancer Immunol Immunother (1992) 0.77
Natural killer cells adhere to bone marrow fibroblasts and inhibit adhesion of acute myeloid leukemia cells. Leukemia (1995) 0.76
Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples. Nat Immun (1992) 0.76
Treatment of chronic myelogenous leukemia with interleukin-2: a phase II study in 21 patients. J Immunother (1999) 0.76
Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant (1994) 0.76
Lysis of human leukemic cells by monocyte-derived macrophages activated with interferon-gamma and interleukin-2. Jpn J Cancer Res (1989) 0.76
Effect of administration of BCG, levamisole and irradiated leukemic cells on immune status and remission status in chronic myelogenous leukemia. Oncology (1985) 0.76
Immunotherapy of human leukemia with antibody to pluripotential K-562 stem cells. J Cancer Res Clin Oncol (1983) 0.76
Antibody responses to leukemia-associated antigens during immunotherapy of chronic myelocytic leukemia. Blood (1975) 0.76
BCR/ABL- CD34(+)HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal. Blood (1999) 0.76
Chronic myelocytic leukemia--Part II: Approaches to and molecular monitoring of therapy. Clin Lab Sci (2005) 0.75
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood (2013) 8.00
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med (2007) 7.91
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood (2006) 4.40
Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis (2004) 3.10
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis (2011) 2.19
Endometrial regenerative cells: a novel stem cell population. J Transl Med (2007) 2.19
Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol Dis (2005) 1.93
A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood (2002) 1.89
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med (2009) 1.62
Novel small interfering RNA-containing solution protecting donor organs in heart transplantation. Circulation (2009) 1.60
Cutaneous sarcoidosis and malignancy: An association between sarcoidosis with skin manifestations and systemic neoplasia. Dermatol Online J (2011) 1.49
Polycystic ovary syndrome: focus on platelets and prothrombotic risk. South Med J (2011) 1.44
Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol (2003) 1.41
Malignant melanoma in pigmented skin: does the current interventional model fit a different clinical, histologic, and molecular entity? Dermatol Surg (2013) 1.41
Early lymphocyte recovery at 28 d post-transplant is predictive of reduced risk of relapse in patients with acute myeloid leukemia transplanted with peripheral blood stem cell grafts. Eur J Haematol (2014) 1.39
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol (2009) 1.35
Exosomes as a tumor immune escape mechanism: possible therapeutic implications. J Transl Med (2008) 1.28
Allogeneic endometrial regenerative cells: an "Off the shelf solution" for critical limb ischemia? J Transl Med (2008) 1.27
Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica (2008) 1.27
Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol (2009) 1.22
Clinical and genetic analysis of unclassifiable inherited bone marrow failure syndromes. Pediatrics (2008) 1.19
Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy. Cell Immunol (2010) 1.19
A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion (2007) 1.17
Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res (2009) 1.16
Orthomolecular oncology review: ascorbic acid and cancer 25 years later. Integr Cancer Ther (2005) 1.15
Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol (2003) 1.11
Feasibility investigation of allogeneic endometrial regenerative cells. J Transl Med (2009) 1.10
Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report. Int Arch Med (2010) 1.09
Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions. J Transl Med (2010) 1.09
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymphoma Myeloma Leuk (2013) 1.08
A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J (2005) 1.08
Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem (2006) 1.07
Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant (2005) 1.07
Myocyte enhancer factor 2C as a neurogenic and antiapoptotic transcription factor in murine embryonic stem cells. J Neurosci (2008) 1.06
Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res Ther (2006) 1.06
Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance. Biol Blood Marrow Transplant (2007) 1.06
A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood (2009) 1.04
Selective apoptosis of breast cancer cells by siRNA targeting of BORIS. Biochem Biophys Res Commun (2008) 1.03
Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leuk Res (2008) 1.03
Tumor vaccines in 2010: need for integration. Cell Immunol (2010) 1.02
The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol (2005) 1.01
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol (2013) 0.98
Cord blood in regenerative medicine: do we need immune suppression? J Transl Med (2007) 0.97
Endometrial regenerative cells for treatment of heart failure: a new stem cell enters the clinic. J Transl Med (2013) 0.96
Intravenous ascorbic acid: protocol for its application and use. P R Health Sci J (2003) 0.96
Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells. J Immunol (2010) 0.96
Generation of therapeutic dendritic cells and regulatory T cells for preventing allogeneic cardiac graft rejection. Clin Immunol (2008) 0.95
Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. P R Health Sci J (2008) 0.95
Intravenous vitamin C as a chemotherapy agent: a report on clinical cases. P R Health Sci J (2004) 0.95
A novel in vivo siRNA delivery system specifically targeting liver cells for protection of ConA-induced fulminant hepatitis. PLoS One (2012) 0.94
Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy. Am J Hematol (2008) 0.94
Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations. J Mol Diagn (2007) 0.93
Placental mesenchymal and cord blood stem cell therapy for dilated cardiomyopathy. Reprod Biomed Online (2008) 0.93
Long-term survival after blood and marrow transplantation: comparison with an age- and gender-matched normative population. Biol Blood Marrow Transplant (2006) 0.93
Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia. Blood (2009) 0.93
Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol (2007) 0.93
Outcomes of older patients (> or = 60 years) with acquired aplastic anaemia treated with immunosuppressive therapy. Br J Haematol (2008) 0.93
Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting. J Immunol (2003) 0.93
Comparison of endometrial regenerative cells and bone marrow stromal cells. J Transl Med (2012) 0.92
Anti-angiogenic effect of high doses of ascorbic acid. J Transl Med (2008) 0.92
Stem cell therapy for autism. J Transl Med (2007) 0.91
Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver. Transfus Apher Sci (2002) 0.91
LF15-0195 generates tolerogenic dendritic cells by suppression of NF-kappaB signaling through inhibition of IKK activity. J Leukoc Biol (2003) 0.91
Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leuk Lymphoma (2004) 0.90
A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia. Blood (2011) 0.90
Small interfering RNA targeting RelB protects against renal ischemia-reperfusion injury. Transplantation (2009) 0.89
Cancer is a functional repair tissue. Med Hypotheses (2005) 0.89
Acute leukemia of donor origin arising after stem cell transplantation for acute promyelocytic leukemia. Leuk Res (2004) 0.89
Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood (2013) 0.89
Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2012) 0.88
RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis. Arthritis Res Ther (2010) 0.88
Human umbilical cord blood-derived mononuclear cell transplantation: case series of 30 subjects with hereditary ataxia. J Transl Med (2011) 0.88
The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res (2010) 0.88
Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer (2012) 0.87
Successful penile replantation with adjuvant hyperbaric oxygen treatment. Urology (2007) 0.87
Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL). Leuk Res (2005) 0.87
Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia. Cytokines Cell Mol Ther (2002) 0.87
L-ascorbic acid represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. J Cell Biochem (2004) 0.87
Autologous stromal vascular fraction cells: a tool for facilitating tolerance in rheumatic disease. Cell Immunol (2010) 0.86
The king is dead, long live the king: entering a new era of stem cell research and clinical development. J Transl Med (2011) 0.86
Inhibition of intracranial glioma growth by endometrial regenerative cells. Cell Cycle (2009) 0.85
Combination stem cell therapy for heart failure. Int Arch Med (2010) 0.85
Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant (2009) 0.85
A simple and reliable method to blood type monkeys using serum samples. Transpl Int (2009) 0.85
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol. Br J Haematol (2012) 0.85
Small cell lung cancer with paraneoplastic lipase production. South Med J (2010) 0.85